Skip to main content
Premium Trial:

Request an Annual Quote

Caprion Acquired by GHO Capital

NEW YORK (GenomeWeb) – Proteomics firm Caprion Biosciences said today that it has been acquired by London-based healthcare investment firm GHO Capital.

GHO purchased the company for an undisclosed amount from Chicago Growth Partners, Caprion's majority shareholder since 2012. Caprion said that it will continue to operate out of its current Montreal headquarters under the leadership of its existing management team.

Caprion provides immunology and proteomics research services to pharmaceutical and biotechnology companies. The firm is also developing its own in-house diagnostics, with its first planned offering a proteomic test for detecting the onset of diabetes and managing the disease.

In a statement, Caprion CEO Martin LeBlanc called the GHO deal a "very successful outcome" for the company's investors and "tangible evidence of the strong business performance and growth that Caprion has achieved during our four-year partnership with Chicago Growth Partners."

The Scan

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.

Meta AI Computer Model Rapidly Predicts Hundreds of Millions of Metagenomic Proteins

Meta AI researchers describe in Science a new large language model that can predict the structures of millions of metagenomic proteins.

Hutch Team Develops Platform for Assessing Impact of SARS-CoV-2 Spike Mutations

The approach described in Cell relies on lentiviral pseudotyping for mutational scanning, which the researchers applied to the SARS-CoV-2 spike protein.

Potential New Therapeutic Target for Rheumatoid Arthritis Discovered

Researchers report in the American Journal of Human Genetics that SNPs implicated in rheumatoid arthritis often regulate the expression of the inflammation-related SPRED2 gene.